tenofovir alafenamide (Vemlidy)
in the absence of a submission from the holder of the marketing authorisation:
tenofovir alafenamide (Vemlidy®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
|Drug Name:||tenofovir alafenamide (Vemlidy)|
|SMC Drug ID:||1238/17|
|Manufacturer:||Gilead Sciences Ltd|
|Indication:||Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).|
|Submission Type:||Non submission|
|Date Advice Published:||10 April 2017|